Posted by Michael Wonder on 09 Mar 2016
Vertex receives Australian approval for Orkambi (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation
8 March 2016 - The Australian reimbursement process for Orkambi is already underway as part of the parallel regulatory and reimbursement processes between the TGA and the PBAC.
For more details, go to: http://www.businesswire.com/news/home/20160308006634/en/Vertex-Receives-Australian-Approval-ORKAMBI®-lumacaftorivacaftor-Medicine
